| PRE – fast track (n = 151) | Fast-track (n = 151) | P value |
---|---|---|---|
Age, years, mean ± SD | 80.7 ± 7.51 | 79.7 ± 7.85 | 0.272 |
  ≥ 85 years, n (%) | 43 (28.5) | 43 (28.5) | 1.000 |
Female, n (%) | 107 (70.9) | 113 (74.8) | 0.438 |
BMI, kg/m2, mean ± SD | 21.89 ± 4.14 | 22.01 ± 3.56 | 0.783 |
  < 18.5 | 35 (23.2) | 23 (15.2) | 0.349 |
 18.5–22.9 | 62 (41.1) | 76 (50.3) |  |
 23.0–24.9 | 20 (13.2) | 21 (13.9) |  |
 25.0–29.9 | 29 (19.2) | 28 (18.5) |  |
  ≥ 30 | 5 (3.3) | 3 (2.0) |  |
Comorbidities, n (%) | |||
 Diabetes mellitus | 57 (37.7) | 52 (34.4) | 0.549 |
 Hypertension | 120 (79.5) | 119 (78.8) | 0.887 |
 Ischemic heart disease | 25 (16.6) | 21 (13.9) | 0.522 |
 Congestive heart failure | 4 (2.6) | 4 (2.6) | 1.000 |
 Cerebrovascular disease | 34 (22.5) | 38 (25.2) | 0.589 |
 COPD, Bronchiectasis or Asthma | 9 (6.0) | 5 (3.3) | 0.274 |
 CKD Stage 3–5 | 33 (21.9) | 36 (23.8) | 0.681 |
 ESRD on HD/CAPD | 5 (3.3) | 6 (4.0) | 0.759 |
 Dementia | 36 (23.8) | 56 (37.1) | 0.012 |
Charlson Comorbidity Index (CCI), n (%) | Â | Â | 0.494 |
 2 | 7 (4.6) | 6 (4.0) |  |
 3 | 10 (6.6) | 18 (11.9) |  |
 4 | 38 (25.2) | 28 (18.5) |  |
 5 | 26 (17.2) | 34 (22.5) |  |
  ≥ 6 | 70 (46.4) | 65 (43.1) |  |
Education, years, n (%) | Â | Â | 0.479 |
  ≤ 4 | 95 (62.9) | 89 (58.9) |  |
  > 4 | 56 (37.1) | 62 (41.1) |  |
Polypharmacy, n (%) | Â | Â | 0.120 |
  < 5 | 32 (21.2) | 34 (22.5) |  |
 5–10 | 64 (42.4) | 76 (50.3) |  |
  > 10 | 55 (36.4) | 41 (27.2) |  |
BADL, Dependent, n (%) | 21 (13.9) | 22 (14.6) | 0.869 |
IADL, Dependent, n (%) | 51 (33.8) | 59 (39.1) | 0.339 |
Hematocrit, %, mean ± SD | 34.71 ± 6.02 | 34.95 ± 5.52 | 0.711 |
WBC count, cell/mm3, mean ± SD | 10,059.00 ± 3306.11 | 10,525.56 ± 3686.88 | 0.249 |
Serum albumin (pre-op), g/dl, mean ± SD | 3.74 ± 0.54 | 3.76 ± 0.50 | 0.707 |
Vitamin D level, ng/mL, mean ± SD (n = 284) | n = 136 18.38 ± 9.84 | n = 148 19.36 ± 9.42 | 0.393 |
  ≥ 30 | 16 (11.8) | 18 (12.2) | 0.211 |
 20–29a | 31 (22.8) | 47 (31.8) |  |
  < 20b | 89 (65.4) | 83 (56.1) |  |